Breast cancer is a malignant neoplasm that begins in
the breast tissue. Most breast cancers are invasive cancers that have
grown beyond the ducts or lobules and can metastasize to other parts of
the body through the bloodstream and the lymphatic system. Broadly,
patients can be segmented into two types: the human epidermal growth
factor receptor (HER) 2-negative segment and the HER2-positive segment.
HER2-positive breast cancer is aggressive and, historically, has had a
worse overall survival than HER2-negative disease, which is considered
less aggressive.
In HER2-negative breast cancer, a number of different factors can influence the choice of therapy that a patient receives, including the stage of the cancer, the hormonal receptor status of the cancer (ER-positive or -negative and PR-positive or -negative) and whether the patient is a BRCA-mutation carrier. Triple-negative breast cancer (TNBC) is a setting with incredibly high unmet needs, with no targeted therapy options being available. Chemotherapy is the mainstay of treatment in this setting. For HR-positive disease, endocrine therapies are the primary treatment.
Browse Detail Report With TOC @ http://www.hexareports.com/report/breast-cancer-therapeutics-in-southeast-asia-markets-to-2022
Survival for HER2-positive breast cancer patients has increased, due to established disease management strategies using numerous combinations of chemotherapy along with targeted therapies such as Herceptin, Tykerb (lapatinib) and Perjeta (pertuzumab). These newer therapies are expected to significantly improve survival outcomes in all lines of the disease. The introduction of Herceptin, the first HER2-targeting agent for metastatic disease, greatly improved the outcome of patients with HER2-positive breast cancer, bringing survival rates close to those of HER2-negative, HR-positive breast cancer.
In most Southeast Asian countries, the highest unmet need lies in the lack of a defined treatment plan for the disease, poor affordability, and patients continuing to rely on the use of chemotherapies in the later lines of treatment. It is important for drug companies to consider the evolving reimbursement landscape when determining pricing strategies across the Southeast Asian markets, because this will significantly impact the uptake of premium drugs.
Request A Sample copy of This Report @ http://www.hexareports.com/report/breast-cancer-therapeutics-in-southeast-asia-markets-to-2022/request-sample
Scope
Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022 -
http://www.hexareports.com/report/rheumatoid-arthritis-therapeutics-in-south-east-asia-markets-to-2022
Antibacterial Therapies Drug Development Pipeline Review, 2017 -
http://www.hexareports.com/report/antibacterial-therapies-drug-development-pipeline-review-2017
Neurodegenerative Disorders Drug Development Pipeline Review, 2017 -
http://www.hexareports.com/report/neurodegenerative-disorders-drug-development-pipeline-review-2017
In HER2-negative breast cancer, a number of different factors can influence the choice of therapy that a patient receives, including the stage of the cancer, the hormonal receptor status of the cancer (ER-positive or -negative and PR-positive or -negative) and whether the patient is a BRCA-mutation carrier. Triple-negative breast cancer (TNBC) is a setting with incredibly high unmet needs, with no targeted therapy options being available. Chemotherapy is the mainstay of treatment in this setting. For HR-positive disease, endocrine therapies are the primary treatment.
Browse Detail Report With TOC @ http://www.hexareports.com/report/breast-cancer-therapeutics-in-southeast-asia-markets-to-2022
Survival for HER2-positive breast cancer patients has increased, due to established disease management strategies using numerous combinations of chemotherapy along with targeted therapies such as Herceptin, Tykerb (lapatinib) and Perjeta (pertuzumab). These newer therapies are expected to significantly improve survival outcomes in all lines of the disease. The introduction of Herceptin, the first HER2-targeting agent for metastatic disease, greatly improved the outcome of patients with HER2-positive breast cancer, bringing survival rates close to those of HER2-negative, HR-positive breast cancer.
In most Southeast Asian countries, the highest unmet need lies in the lack of a defined treatment plan for the disease, poor affordability, and patients continuing to rely on the use of chemotherapies in the later lines of treatment. It is important for drug companies to consider the evolving reimbursement landscape when determining pricing strategies across the Southeast Asian markets, because this will significantly impact the uptake of premium drugs.
Request A Sample copy of This Report @ http://www.hexareports.com/report/breast-cancer-therapeutics-in-southeast-asia-markets-to-2022/request-sample
Scope
- Which drugs are used as the standard treatment in each setting of the disease?
What are the competitive advantages of the existing novel drugs? - Do branded therapies show continued growth, and how does their expected uptake influence the market growth over the forecast period?
- There are about 1,150 active pipeline molecules. The pipeline contains a range of molecule types and
- Which molecular targets appear most frequently in the pipeline?
- There is currently no approved therapy in the TNBC setting. Are there any drugs in the pipeline to improve treatment for TNBC?
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the breast cancer market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are also highlighted to allow a competitive understanding of gaps in the market.
- Analyze the breast cancer pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict breast cancer market growth in the eight Southeast Asian markets, with epidemiological and annual cost of therapy forecasts, as well as analysis of the contributions of promising late-stage molecules to market growth.
- Identify commercial opportunities in the breast cancer deals landscape by analyzing trends in licensing and co-development deals.
Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022 -
http://www.hexareports.com/report/rheumatoid-arthritis-therapeutics-in-south-east-asia-markets-to-2022
Antibacterial Therapies Drug Development Pipeline Review, 2017 -
http://www.hexareports.com/report/antibacterial-therapies-drug-development-pipeline-review-2017
Neurodegenerative Disorders Drug Development Pipeline Review, 2017 -
http://www.hexareports.com/report/neurodegenerative-disorders-drug-development-pipeline-review-2017
No comments:
Post a Comment